SCHEMBL25608131

SCHEMBL25608131

C[C@@H]1CN(C(=O)OC(C)(C)C)CC1C(=O)O

nearest known ligand 0.71

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
▸ NR1H2 P55055 1/20 0.49
▸ USP2 O75604 1/20 0.47
▸ SMN1; SMN2 Q16637 1/20 0.47
▸ PDE4B Q07343 2/20 0.44
▸ RECQL P46063 1/20 0.42
▸ HPGD P15428 1/20 0.41
▸ RORC P51449 1/20 0.40
▸ GPR119 Q8TDV5 1/20 0.39
▸ USP30 Q70CQ3 2/20 0.39
▸ EPHX1 P07099 1/20 0.39
▸ HSD17B10 Q99714 1/20 0.38
▸ DDB1 Q16531 1/20 0.38
▸ CRBN Q96SW2 1/20 0.38
▸ NAMPT P43490 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24707902 1.00 NR1H2 (0.49) NR1H2USP2SMN1; SMN2PDE4BRECQL
SCHEMBL30342352 1.00 NR1H2 (0.49) NR1H2USP2SMN1; SMN2PDE4BRECQL
SCHEMBL10137666 1.00 NR1H2 (0.49) NR1H2USP2SMN1; SMN2PDE4BRECQL
SCHEMBL10137667 1.00 NR1H2 (0.49) NR1H2USP2SMN1; SMN2PDE4BRECQL
SCHEMBL10137713 1.00 NR1H2 (0.49) NR1H2USP2SMN1; SMN2PDE4BRECQL
SCHEMBL6065186 0.91 NR1H2 (0.53) NR1H2USP2SMN1; SMN2PDE4BRECQL
SCHEMBL1052921 0.91 NR1H2 (0.53) NR1H2USP2SMN1; SMN2PDE4BRECQL
SCHEMBL1051376 0.91 NR1H2 (0.53) NR1H2USP2SMN1; SMN2PDE4BRECQL
SCHEMBL10585442 0.88 NR1H2 (0.45) NR1H2USP2SMN1; SMN2PDE4BRECQL
SCHEMBL10054586 0.86 NR1H2 (0.49) NR1H2USP2SMN1; SMN2PDE4BRECQL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230183255-A1 PDE9 INHIBITORS WITH IMIDAZO TRIAZINONE BACKBONE AND IMIDAZO PYRAZINONE BACKBONE FOR TREATMENT OF PERIPHERAL DISEASES H. LUNDBECK A/S (DK) 2023-06-15 — — US disclosed
US-20230183255-A1 PDE9 INHIBITORS WITH IMIDAZO TRIAZINONE BACKBONE AND IMIDAZO PYRAZINONE BACKBONE FOR TREATMENT OF PERIPHERAL DISEASES H. LUNDBECK A/S (DK) 2023-06-15 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230183255-A1 PDE9 INHIBITORS WITH IMIDAZO TRIAZINONE BACKBONE AND IMIDAZO PYRAZINONE BACKBONE FOR TREATMENT OF PERIPHERAL DISEASES PDE9A, PDE5A, PDE3A NR1H2 1711/4885USP2 4239/4885SMN1; SMN2 552/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback